Close
What would you like to look for?

14 December 2018

Resistell has closed an oversubscribed seed financing round. Lead Investors Michal Bartos and Occident Group AG, together with Hemex AG and five other private investors invested in the EPFL spin-off developing the world’s fastest phenotypic antibiotic susceptibility test identifying drug resistance within hours instead of days. Resistell AG was incorporated in April 2018 in Basel to take the technology to the next level and to transfer the laboratory prototypes into a Minimal Viable Product that could be easily operated by laboratory technicians in hospital laboratories.

VISCHER AG advised Resistell, the team was led by Matthias Staehelin (Partner) with Luzius Zumstein (Associate) both Corporate.

Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk, Deals & Cases

Authors